false
0001468492
0001468492
2026-11-18
2026-11-18
0001468492
us-gaap:CommonStockMember
2026-11-18
2026-11-18
0001468492
HSCS:WarrantsMember
2026-11-18
2026-11-18
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest
event reported): November 18, 2026
HEARTSCIENCES INC.
(Exact name of Registrant as Specified in Its
Charter)
| Texas |
|
001-41422 |
|
26-1344466 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
| 550 Reserve Street, Suite 360 |
|
|
| Southlake, Texas |
|
76092 |
| (Address of Principal Executive Offices) |
|
(Zip Code) |
| |
|
|
| Registrant’s Telephone Number, Including Area Code: (682) 237-7781 |
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ☒ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on
which registered |
| Common Stock |
|
HSCS |
|
The Nasdaq Stock Market LLC |
| Warrants |
|
HSCSW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 1.01 Entry into a Material Definitive Agreement.
On November 18, 2026, HeartSciences
Inc. (the “Company” or “HeartSciences”) entered into an Equity Distribution Agreement (the “EDA”)
with Maxim Group LLC (“Maxim Group”) as sales agent, pursuant to which the Company may offer and sell, from time to time,
an aggregate of up to $50,000,000 of its shares of common stock, $0.001 par value per share (the “Shares”), in an “at
the market offering” (as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended (the “Securities Act”)).
The Shares may be issued
and sold from time to time through or to Maxim Group acting as sales agent or principal pursuant to the Company’s shelf
Registration Statement on Form S-3, as amended (File No. 333-299147), as declared effective by the U.S. Securities and Exchange Commission (the
“SEC”) on November 17, 2026 (the “Registration Statement”). The Company will file a prospectus supplement,
dated November 19, 2026, pursuant to Rule 424(b) under the Securities Act with respect to the Shares (the “Prospectus
Supplement”). Sales of the Shares, if any, under the Prospectus Supplement may be made in transactions that are deemed to be
“at the market offerings” pursuant to Rule 415 under the Securities Act. Pursuant to General Instruction I.B.6 of Form
S-3, the Company may not sell the shelf securities in a public primary offering with a value exceeding more than one-third of the
aggregate market value of its voting and non-voting common shares held by non-affiliates in any 12-month period as long as the
aggregate market value of the Company’s outstanding common shares held by non-affiliates is less than $75 million.
Accordingly, although the EDA provides for the sale of up to $50,000,000 of Shares, which amount is included in the $200,000,000 of
securities that may be offered, issued and sold by the Company under the base prospectus included in the Registration Statement, the
Prospectus Supplement covers the offer and sale of Shares having an aggregate offering price of up to $3,077,649.
Under the EDA, Shares may
be sold by any method permitted by law deemed to be an “at the market offering.” Maxim Group will also be able to sell Shares
by any other method permitted by law, including in negotiated transactions with the Company’s prior written consent. Upon delivery
of a placement notice and subject to the terms and conditions of the EDA, Maxim Group is required to use its commercially reasonable efforts
consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations, and the rules of The
Nasdaq Capital Market to sell the Shares from time to time based upon the Company’s instructions, including any price, time or size
limits specified by the Company. Maxim Group is not under any obligation to purchase any of the Shares on a principal basis pursuant to
the EDA. Maxim Group’s obligations to sell the Shares under the EDA are subject to satisfaction of certain conditions, including
customary closing conditions.
The EDA contains representations,
warranties and covenants that are customary for transactions of this type. The Company will pay Maxim Group a commission equal to (x)
2.5%, for so long as the Company is subject to the limitations of General Instruction I.B.6 of Form S-3, and (y) 2.0% thereafter, for
so long as the Company is not subject to the limitations of General Instruction I.B.6 of Form S-3, if any, of the gross sales price per
share for any Shares sold through Maxim Group under the EDA. The Company will also reimburse Maxim Group’s legal fees and expenses
up to $15,000 in connection with the preparation and entering into the EDA plus up to $5,000 per Bringdown Date (as defined in the EDA).
The Company has provided Maxim Group with customary indemnification and contribution rights. The EDA may be terminated by Maxim Group
or the Company at any time upon notice to the other party as provided in the EDA, or by Maxim Group at any time in certain circumstances,
including the occurrence of a material and adverse change in the Company’s business or financial condition that makes it impractical
or inadvisable to market the Shares or to enforce contracts for the sale of the Shares.
This Current Report on Form
8-K (this “Current Report”) shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be
any sale of the Shares in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state.
The foregoing description is
a summary only, does not purport to set forth the complete terms of the EDA and is qualified in its entirety by reference to the EDA
filed as Exhibit 1.1 to this Current Report and incorporated herein by reference. The
legal opinion of Foley Shechter Ablovatskiy LLP, counsel to the Company, relating to the validity of the Shares being offered pursuant
to the EDA is filed as Exhibit 5.1 to this Current Report and is incorporated herein by reference.
Additional Information
and Where to Find It
As previously reported,
on June 23, 2026, the Company and Fortitude Mining Holdings, Inc. (“Fortitude”), a vertically-integrated digital asset mining
platform anchored in Zcash, entered into a definitive merger agreement (as amended, the “Merger Agreement”) to combine in
an all-stock transaction (the “Proposed Transaction”). The following is important information that should be read together
with this Current Report.
Communications related to
each of Fortitude and HeartSciences, their respective businesses and the Proposed Transaction may be deemed solicitation material in
respect of the Proposed Transaction. In connection with the Proposed Transaction, on October 19, 2026, HeartSciences filed a
definitive proxy statement on Schedule 14A (the “Definitive Proxy Statement”) with the SEC, and has filed and may file
additional relevant materials with the SEC from time to time. HeartSciences has mailed the Definitive Proxy Statement and a proxy
card to each shareholder entitled to vote at the special meeting relating to the Proposed Transaction. INVESTORS AND SHAREHOLDERS OF
HEARTSCIENCES ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS
IN CONNECTION WITH THE PROPOSED TRANSACTION THAT HEARTSCIENCES HAS FILED OR MAY FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE
THEY CONTAIN IMPORTANT INFORMATION ABOUT HEARTSCIENCES AND THE PROPOSED TRANSACTION. COMMUNICATIONS THAT DO NOT CONTAIN ALL THE
INFORMATION THAT SHOULD BE CONSIDERED CONCERNING THE PROPOSED TRANSACTION AND RELATED MATTERS ARE NOT INTENDED TO PROVIDE THE BASIS
FOR ANY INVESTMENT DECISION OR ANY OTHER DECISION IN RESPECT OF SUCH MATTERS. The Definitive Proxy Statement, the preliminary proxy
statement and other relevant materials in connection with the Proposed Transaction (when they become available), and any other
documents filed by HeartSciences with the SEC, may be obtained free of charge at the SEC’s website at www.sec.gov. In
addition, investors and shareholders may obtain free copies of the documents filed with the SEC or by sending a request to the
HeartSciences Investor Relations Department at investorrelations@heartsciences.com.
NEITHER
THE SEC NOR ANY STATE SECURITIES REGULATORY AGENCY HAS APPROVED OR DISAPPROVED THE TRANSACTIONS DESCRIBED HEREIN, PASSED UPON THE MERITS
OR FAIRNESS OF THE PROPOSED TRANSACTION OR ANY RELATED TRANSACTIONS OR PASSED UPON THE ADEQUACY OR ACCURACY OF THE DISCLOSURE IN THIS
CURRENT REPORT. ANY REPRESENTATION TO THE CONTRARY CONSTITUTES A CRIMINAL OFFENSE.
Cautionary Note Regarding
Forward-Looking Information
This
Current Report may contain forward-looking statements concerning HeartSciences, Fortitude and the Proposed Transaction and other matters.
These forward-looking statements generally can be identified by the use of words such as “aim,” “anticipate,”
“expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,”
“forecast,” “goal,” “project,” “potential,” “target,” “objective,”
“intend,” and other words of similar meaning, but the absence of these words does not mean that a statement is not forward-looking.
All statements HeartSciences and/or Fortitude make in communications that do not relate to matters of historical fact should be considered
forward-looking statements.
These forward-looking statements
are based on management’s current expectations and assumptions as of the date of such communication and are subject to a number
of known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed
or implied by such statements, which may include, without limitation, the following: the risk that the Proposed Transaction may not be
completed on the anticipated timeline or at all; the failure to satisfy the conditions to the closing of the Proposed Transaction, including
obtaining the requisite approval of HeartSciences’ shareholders; market, macroeconomic, or other conditions that could adversely
affect either HeartSciences or Fortitude, or the combined company; risks related to the integration of the two companies and the management
of a newly public company; risks relating to Fortitude’s operations and business, including the highly volatile nature of the price
of Zcash and other cryptocurrencies; and risks relating to significant legal, commercial, regulatory and technical uncertainty regarding
digital assets generally. Additional factors that may cause actual results to differ materially from those expressed or implied by the
forward-looking statements in such communications are discussed in the Definitive Proxy Statement, HeartSciences’ 2026 Annual Report
on Form 10-K, filed with the SEC on July 23, 2026, its Quarterly Report on Form 10-Q for the fiscal quarter ended July 31, 2026, filed
with the SEC on September 14, 2026, and its other reports filed with the SEC from time to time. Readers are cautioned not to place undue
reliance on these forward-looking statements. Each of HeartSciences and Fortitude expressly disclaims any obligation to update or revise
any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable
law. Any forward-looking statements made in such communications are made as of the date of the communication. All information provided
in this Current Report is as of November 19, 2026, and the Company undertakes no duty to update this information unless required by law.
Participants in the
Solicitation
HeartSciences
and Fortitude, their respective directors and executive officers, and certain executive officers of Digital Currency Group, Inc. (“DCG”),
the parent company of Fortitude, may be deemed to be participants in the solicitation of proxies from HeartSciences’ shareholders
with respect to the Proposed Transaction. Information regarding the identity of the potential participants, and their direct or indirect
interests in the Proposed Transaction, by security holdings or otherwise, is set forth in the Definitive Proxy Statement and other materials
that have been or may be filed with the SEC in connection with the Proposed Transaction.
In
the ordinary course of business, Fortitude currently sells or otherwise monetizes all the digital assets that it mines, including ZEC.
In addition, Fortitude and its affiliates and subsidiaries, including DCG, from time to time sell, pledge or otherwise monetize their
digital asset holdings, including ZEC. The funds received from such sales, pledges, or other monetization activities are used to fund
operating expenses and capital investments, as well as for other purposes, including to hedge exposures and realize investment gains.
No Offer or Solicitation
Any
information contained herein is not intended to and does not constitute, or form part of, an offer, invitation or the solicitation of
an offer or invitation to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities, or the solicitation
of any vote or approval in any jurisdiction, pursuant to the Proposed Transaction or otherwise, nor shall there be any sale, issuance
or transfer of securities in any jurisdiction in contravention of applicable law. The Proposed Transaction will be implemented solely
pursuant to the terms and conditions of the Merger Agreement, which contain the full terms and conditions of the Proposed Transaction.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. |
|
Description |
| 1.1* |
|
Equity Distribution Agreement, dated as of November 18, 2026, between the Company and Maxim Group LLC. |
| 5.1* |
|
Opinion of Foley Shechter Ablovatskiy LLP. |
| 23.1* |
|
Consent of Foley Shechter Ablovatskiy LLP (contained in Exhibit 5.1). |
| 104* |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
HEARTSCIENCES INC. |
| |
|
|
| Date: November 19, 2026 |
By: |
/s/ Andrew Simpson |
| |
Name:
|
Andrew Simpson |
| |
Title: |
President, Chief Executive Officer and
Chairman of the Board of Directors |